Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: Estimations of the number needed to treat based on competing-risks analysis

Giorgio Gandaglia, Maxine Sun, Quoc Dien Trinh, Andreas Becker, Jonas Schiffmann, Jim C. Hu, Alberto Briganti, Francesco Montorsi, Paul Perrotte, Pierre I. Karakiewicz, Firas Abdollah

Research output: Contribution to journalArticle

Abstract

Objective To describe the survival benefit associated with radical prostatectomy (RP), as compared with initial observation, in patients with locally advanced prostate cancer (PCa).

Patients and Methods Overall, 1382 patients with locally advanced PCa treated with RP or initial observation between 1995 and 2009 were identified from the Surveillance, Epidemiology and End Results Medicare insurance programme-linked database. Patients were matched using propensity-score methodology, then 10-year cancer-specific mortality (CSM) rates were estimated and the number needed to treat (NNT) was calculated. Competing-risks regression analyses tested the relationship between treatment type and CSM.

Results Overall, the 10-year CSM rates were 11.8 and 19.3% for patients treated with RP and initial observation, respectively (P <0.001). The corresponding 10-year NNT was 13. The 10-year CSM rates for the same treatment groups were 8.9 vs 13.9%, respectively, for Gleason score ≤7, 16.8 vs 27.8%, respectively, for Gleason score 8-10, 10.1 vs 15.8%, respectively, for clinical stage T3a, and 17.0 vs 29.3%, respectively, for T3b/T4, respectively (all P ≤ 0.04). The corresponding NNTs were 20, 9, 17 and 8, respectively. In multivariable analyses, RP was an independent predictor of more favourable CSM rates in all categories (all P ≤ 0.04). In separate sensitivity analyses, no differences were recorded when patients treated with radiotherapy were compared with those receiving RP (P = 0.4). Conversely, patients undergoing initial observation had a higher risk of CSM compared with those treated with radiotherapy (P = 0.03).

Conclusions RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.

Original languageEnglish
Pages (from-to)E62-E69
JournalBJU International
Volume114
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Numbers Needed To Treat
Prostatic Neoplasms
Prostatectomy
Survival
Observation
Mortality
Neoplasm Grading
Neoplasms
Therapeutics
Radiotherapy
Propensity Score
Medicare
Insurance
Epidemiology
Regression Analysis
Databases

Keywords

  • locally-advanced
  • observation
  • prostate cancer
  • radical prostatectomy
  • radiotherapy
  • survival benefit

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Survival benefit of definitive therapy in patients with clinically advanced prostate cancer : Estimations of the number needed to treat based on competing-risks analysis. / Gandaglia, Giorgio; Sun, Maxine; Trinh, Quoc Dien; Becker, Andreas; Schiffmann, Jonas; Hu, Jim C.; Briganti, Alberto; Montorsi, Francesco; Perrotte, Paul; Karakiewicz, Pierre I.; Abdollah, Firas.

In: BJU International, Vol. 114, No. 6, 01.12.2014, p. E62-E69.

Research output: Contribution to journalArticle

Gandaglia, Giorgio ; Sun, Maxine ; Trinh, Quoc Dien ; Becker, Andreas ; Schiffmann, Jonas ; Hu, Jim C. ; Briganti, Alberto ; Montorsi, Francesco ; Perrotte, Paul ; Karakiewicz, Pierre I. ; Abdollah, Firas. / Survival benefit of definitive therapy in patients with clinically advanced prostate cancer : Estimations of the number needed to treat based on competing-risks analysis. In: BJU International. 2014 ; Vol. 114, No. 6. pp. E62-E69.
@article{e53b6c71c54847889d5fb71334684b67,
title = "Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: Estimations of the number needed to treat based on competing-risks analysis",
abstract = "Objective To describe the survival benefit associated with radical prostatectomy (RP), as compared with initial observation, in patients with locally advanced prostate cancer (PCa).Patients and Methods Overall, 1382 patients with locally advanced PCa treated with RP or initial observation between 1995 and 2009 were identified from the Surveillance, Epidemiology and End Results Medicare insurance programme-linked database. Patients were matched using propensity-score methodology, then 10-year cancer-specific mortality (CSM) rates were estimated and the number needed to treat (NNT) was calculated. Competing-risks regression analyses tested the relationship between treatment type and CSM.Results Overall, the 10-year CSM rates were 11.8 and 19.3{\%} for patients treated with RP and initial observation, respectively (P <0.001). The corresponding 10-year NNT was 13. The 10-year CSM rates for the same treatment groups were 8.9 vs 13.9{\%}, respectively, for Gleason score ≤7, 16.8 vs 27.8{\%}, respectively, for Gleason score 8-10, 10.1 vs 15.8{\%}, respectively, for clinical stage T3a, and 17.0 vs 29.3{\%}, respectively, for T3b/T4, respectively (all P ≤ 0.04). The corresponding NNTs were 20, 9, 17 and 8, respectively. In multivariable analyses, RP was an independent predictor of more favourable CSM rates in all categories (all P ≤ 0.04). In separate sensitivity analyses, no differences were recorded when patients treated with radiotherapy were compared with those receiving RP (P = 0.4). Conversely, patients undergoing initial observation had a higher risk of CSM compared with those treated with radiotherapy (P = 0.03).Conclusions RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.",
keywords = "locally-advanced, observation, prostate cancer, radical prostatectomy, radiotherapy, survival benefit",
author = "Giorgio Gandaglia and Maxine Sun and Trinh, {Quoc Dien} and Andreas Becker and Jonas Schiffmann and Hu, {Jim C.} and Alberto Briganti and Francesco Montorsi and Paul Perrotte and Karakiewicz, {Pierre I.} and Firas Abdollah",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/bju.12645",
language = "English",
volume = "114",
pages = "E62--E69",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Survival benefit of definitive therapy in patients with clinically advanced prostate cancer

T2 - Estimations of the number needed to treat based on competing-risks analysis

AU - Gandaglia, Giorgio

AU - Sun, Maxine

AU - Trinh, Quoc Dien

AU - Becker, Andreas

AU - Schiffmann, Jonas

AU - Hu, Jim C.

AU - Briganti, Alberto

AU - Montorsi, Francesco

AU - Perrotte, Paul

AU - Karakiewicz, Pierre I.

AU - Abdollah, Firas

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective To describe the survival benefit associated with radical prostatectomy (RP), as compared with initial observation, in patients with locally advanced prostate cancer (PCa).Patients and Methods Overall, 1382 patients with locally advanced PCa treated with RP or initial observation between 1995 and 2009 were identified from the Surveillance, Epidemiology and End Results Medicare insurance programme-linked database. Patients were matched using propensity-score methodology, then 10-year cancer-specific mortality (CSM) rates were estimated and the number needed to treat (NNT) was calculated. Competing-risks regression analyses tested the relationship between treatment type and CSM.Results Overall, the 10-year CSM rates were 11.8 and 19.3% for patients treated with RP and initial observation, respectively (P <0.001). The corresponding 10-year NNT was 13. The 10-year CSM rates for the same treatment groups were 8.9 vs 13.9%, respectively, for Gleason score ≤7, 16.8 vs 27.8%, respectively, for Gleason score 8-10, 10.1 vs 15.8%, respectively, for clinical stage T3a, and 17.0 vs 29.3%, respectively, for T3b/T4, respectively (all P ≤ 0.04). The corresponding NNTs were 20, 9, 17 and 8, respectively. In multivariable analyses, RP was an independent predictor of more favourable CSM rates in all categories (all P ≤ 0.04). In separate sensitivity analyses, no differences were recorded when patients treated with radiotherapy were compared with those receiving RP (P = 0.4). Conversely, patients undergoing initial observation had a higher risk of CSM compared with those treated with radiotherapy (P = 0.03).Conclusions RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.

AB - Objective To describe the survival benefit associated with radical prostatectomy (RP), as compared with initial observation, in patients with locally advanced prostate cancer (PCa).Patients and Methods Overall, 1382 patients with locally advanced PCa treated with RP or initial observation between 1995 and 2009 were identified from the Surveillance, Epidemiology and End Results Medicare insurance programme-linked database. Patients were matched using propensity-score methodology, then 10-year cancer-specific mortality (CSM) rates were estimated and the number needed to treat (NNT) was calculated. Competing-risks regression analyses tested the relationship between treatment type and CSM.Results Overall, the 10-year CSM rates were 11.8 and 19.3% for patients treated with RP and initial observation, respectively (P <0.001). The corresponding 10-year NNT was 13. The 10-year CSM rates for the same treatment groups were 8.9 vs 13.9%, respectively, for Gleason score ≤7, 16.8 vs 27.8%, respectively, for Gleason score 8-10, 10.1 vs 15.8%, respectively, for clinical stage T3a, and 17.0 vs 29.3%, respectively, for T3b/T4, respectively (all P ≤ 0.04). The corresponding NNTs were 20, 9, 17 and 8, respectively. In multivariable analyses, RP was an independent predictor of more favourable CSM rates in all categories (all P ≤ 0.04). In separate sensitivity analyses, no differences were recorded when patients treated with radiotherapy were compared with those receiving RP (P = 0.4). Conversely, patients undergoing initial observation had a higher risk of CSM compared with those treated with radiotherapy (P = 0.03).Conclusions RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.

KW - locally-advanced

KW - observation

KW - prostate cancer

KW - radical prostatectomy

KW - radiotherapy

KW - survival benefit

UR - http://www.scopus.com/inward/record.url?scp=84920200879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920200879&partnerID=8YFLogxK

U2 - 10.1111/bju.12645

DO - 10.1111/bju.12645

M3 - Article

C2 - 24467651

AN - SCOPUS:84920200879

VL - 114

SP - E62-E69

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -